Mirae Asset Global ETFs Holdings
HRTX icon

Mirae Asset Global ETFs Holdings’s Heron Therapeutics HRTX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.5K Buy
73,125
+1,756
+2% +$2.04K ﹤0.01% 2866
2025
Q4 		$92.8K Sell
71,369
-491
-0.7% -$606 ﹤0.01% 2713
2025
Q3 		$90.5K Sell
71,860
-11,896
-14% -$18.9K ﹤0.01% 2710
2025
Q2 		$173K Buy
83,756
+13,544
+19% +$27.7K ﹤0.01% 2357
2025
Q1 		$154K Buy
70,212
+2,964
+4% +$5.75K ﹤0.01% 2443
2024
Q4 		$103K Buy
67,248
+2,888
+4% +$4.68K ﹤0.01% 2683
2024
Q3 		$128K Buy
64,360
+2,599
+4% +$6.21K ﹤0.01% 2584
2024
Q2 		$215K Buy
+61,761
New +$190K ﹤0.01% 2209

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's HRTX Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Heron Therapeutics (HRTX) stake by 2.5% in Q1 2026, buying an estimated $2.04K and bringing the position to 73,125 shares worth $58.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2866.

Mirae Asset Global ETFs Holdings first reported a position in HRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $215K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 73,125 shares of Heron Therapeutics worth $58.5K as of Q1 2026.
  • Mirae Asset Global ETFs Holdings bought 1,756 Heron Therapeutics shares in Q1 2026, an estimated $2.04K.
  • Heron Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2866 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Heron Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Mirae Asset Global ETFs Holdings's Heron Therapeutics position peaked at $215K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.